ArticleJournal of imaging informatics in medicine2025
MRI Radiomics-Based Machine Learning to Predict Lymphovascular Invasion of HER2-Positive Breast Cancer.
Article in Journal of imaging informatics in medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Stratifying tumor immune microenvironment in head and neck squamous cell carcinoma: from parsing out immune-subtype prognosis to clinically applicable CT-radiomics models.Journal of translational medicine · 2026Article
- Immune infiltration differences underlying prognostic radiomics subtypes from matched MRI and RNA sequencing in patients with lower-grade gliomas.Discover oncology · 2026Article
- A quantitative method to compare regional tumor contrast between prone and supine breast MRI.Frontiers in oncology · 2026Article
- Decoding Intratumoral Heterogeneity in Breast Cancer: The Evolution From Radiomics to Topological Quantification for Predicting Lymphovascular Invasion.Cancer control : journal of the Moffitt Cancer CenterReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
This study aims to develop and prospectively validate radiomic models based on MRI to predict lymphovascular invasion (LVI) status in patients with HER2-positive breast cancer. A total of 225 patients with HER2-positive breast cancer who preoperatively underwent breast MRI were selected, forming the training set (n = 99 LVI-positive, n = 126 LVI-negative). A prospective validation cohort included 130 patients with breast cancer from the Affiliated Zhongshan Hospital of Dalian University (n = 57 LVI-positive, n = 73 LVI-negative). A total of 390 radiomic features and eight conventional radiological characteristics were extracted. For the optimum feature selection phase, the LASSO regression model with tenfold cross-validation (CV) was employed to identify features with non-zero coefficients. The conventional radiological (CR) model was determined based on visual morphological (VM) features and the optimal radiomic features correlated with LVI, identified through multivariate logistic analyses. Subsequently, various machine learning (ML) models were developed using algorithms such as support vector machine (SVM), k-nearest neighbor (KNN), gradient boosting machine (GBM), and random forest (RF). The performance of ML and CR models. The results show that the AUC of the CR model in the training and validation sets were 0.81 (95% confidence interval [CI], 0.74-0.86) and 0.82 (95% CI, 0.69-0.89), respectively. The ML model achieved the best performance, with AUCs of 0.96 (95% CI, 0.99-1.00) in the training set and 0.95 (95% CI, 0.89-0.96) in the validation set. There were significant differences between the CR and ML models in predicting LVI status. Our study demonstrated that the machine learning models exhibited superior performance in predicting LVI status based on pretreatment MRI compared to the CR model, which does not necessarily rely on a priori knowledge of visual morphology.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.